MX2023013088A - Terapia de celulas t con receptor de antigeno quimerico especifico de cd19. - Google Patents

Terapia de celulas t con receptor de antigeno quimerico especifico de cd19.

Info

Publication number
MX2023013088A
MX2023013088A MX2023013088A MX2023013088A MX2023013088A MX 2023013088 A MX2023013088 A MX 2023013088A MX 2023013088 A MX2023013088 A MX 2023013088A MX 2023013088 A MX2023013088 A MX 2023013088A MX 2023013088 A MX2023013088 A MX 2023013088A
Authority
MX
Mexico
Prior art keywords
antigen receptor
chimeric antigen
cell therapy
specific chimeric
specific
Prior art date
Application number
MX2023013088A
Other languages
English (en)
Spanish (es)
Inventor
Otero Manel Juan
Ispizua Álvaro Urbano
Capdevila Mariona Pascal
Ribes Jordi Yagüe
González Julio Delgado
Reyner Jordi Esteve
Castellà María Castellà
Barado Ana Boronat
Original Assignee
Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer filed Critical Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer
Publication of MX2023013088A publication Critical patent/MX2023013088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023013088A 2021-05-06 2022-05-06 Terapia de celulas t con receptor de antigeno quimerico especifico de cd19. MX2023013088A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (1)

Publication Number Publication Date
MX2023013088A true MX2023013088A (es) 2024-01-24

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013088A MX2023013088A (es) 2021-05-06 2022-05-06 Terapia de celulas t con receptor de antigeno quimerico especifico de cd19.

Country Status (11)

Country Link
US (1) US20240398945A1 (https=)
EP (1) EP4334357A1 (https=)
JP (1) JP2024519529A (https=)
AU (1) AU2022270952A1 (https=)
BR (1) BR112023023061A2 (https=)
CA (1) CA3219214A1 (https=)
CL (1) CL2023003299A1 (https=)
CO (1) CO2023016940A2 (https=)
JO (1) JOP20230269A1 (https=)
MX (1) MX2023013088A (https=)
WO (2) WO2022234158A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
FI2997141T3 (fi) * 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
KR102136063B1 (ko) * 2017-12-06 2020-07-22 앱클론(주) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항체 수용체 및 이의 용도
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12331114B2 (en) * 2018-02-13 2025-06-17 Indian Institute Of Technology Bombay Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
EP3773918A4 (en) * 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
CL2023003299A1 (es) 2024-07-05
CO2023016940A2 (es) 2024-02-05
JOP20230269A1 (ar) 2023-10-26
JP2024519529A (ja) 2024-05-15
US20240398945A1 (en) 2024-12-05
BR112023023061A2 (pt) 2024-01-30
AU2022270952A1 (en) 2023-11-16
EP4334357A1 (en) 2024-03-13
WO2022234158A1 (es) 2022-11-10
CA3219214A1 (en) 2022-11-10
WO2022234134A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2025015210A (es) Receptores de antigeno quimericos dirigidos a cd70
ZA202101358B (en) Chimeric antigen receptors against multiple hla-g isoforms
WO2018118494A3 (en) Use of car-modified human natural killer cells to treat cancer
WO2018098306A8 (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
PH12017500190B1 (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
PH12017502013B1 (en) Anti-ox40 antibodies and methods of use thereof
GEAP202215209A (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
BR112016003417A2 (pt) diacorpo otimizado por sequência capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, diacorpo biespecífico capaz de se ligar especificamente a um epitopo de cd123 e a um epitopo de cd3, composição farmacêutica, e uso da composição farmacêutica
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2019009836A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
PH12019550136A1 (en) ARYL HYDROCARBON RECEPTOR (AhR)MODULATOR COMPOUNDS
MY196831A (en) Aryl hydrocarbon receptor (ahr) modulator compounds
MX390955B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
MY204673A (en) Humanized anti-sirp antibodies
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
PH12022550196A1 (en) Anti-hk2 chimeric antigen receptor (car)
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2023013088A (es) Terapia de celulas t con receptor de antigeno quimerico especifico de cd19.
PH12022551008A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
PH12021553284A1 (en) Prostate specific membrane antigen (psma) ligands and uses thereof